- Home
- ACIU vs CMPS Comparison
ACIU vs CMPS Comparison
Compare ACIU & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | CMPS |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 1.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACIU | CMPS |
|---|---|---|
| Price | $2.82 | $10.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.00 | ★ $25.38 |
| AVG Volume (30 Days) | 248.0K | ★ 5.7M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $706.75 | N/A |
| Revenue Next Year | $321.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.25 |
| 52 Week High | $4.00 | $11.65 |
Technical Indicators
Market Signals| Indicator | ACIU | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 58.72 |
| Support Level | $2.80 | $5.95 |
| Resistance Level | $2.99 | $10.21 |
| Average True Range (ATR) | 0.17 | 0.71 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 30.00 | 53.06 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.